ASAQ registered in 35 countries & territories

More than 516 million treatments distributed

ASAQ Implementation

Click on the map to enlarge and see countries where ASAQ is registered

 

Registration
In February 2007, ASAQ was registered in Morocco, the country of manufacturing of the medicine, a decisive step which enabled rapid exportation to other African countries.

In October 2008, the WHO granted ASAQ a “pre-qualified” status.

Registration applications were submitted in 30 malaria-endemic African countries and approval were obtained in 28 of them between November 2006 and September 2010. ASAQ was also registered in India in 2010.

Field Monitoring Programme
DNDi, Sanofi and additional partners, in particular MMV and National Malaria Control Programmes, are implementing a comprehensive “ASAQ Field Monitoring Programme” that aims to collect high-quality data on ASAQ effectiveness and safety profile in “the field”. This programme includes a series of proactive clinical studies conducted in several countries of sub-Saharan Africa with different levels of disease transmission.
 

Key ongoing studies include two post-registration studies being done in collaboration with MSF, Epicentre, and the National Malaria Control Programme in Liberia. In Ivory Coast, two clinical studies are being set up in collaboration between Sanofi, MMV, and DNDi. Ultimately, more than 20,000 patients will be followed as part of this monitoring plan.

Market and policy surveys
DNDi, in collaboration with African researchers and national malaria control programmes, assessed in 2009 the market of antimalarials in Burundi and Sierra Leone, countries having already adopted ASAQ as first-line treatment for uncomplicated malaria. The results of these surveys provide the groundwork for evidence-based policy implementation of ACTs, which could be translated to other countries with similar socio-demographic and malaria profiles.

 
Year N° treatments distributed
2007 0.5 million
2008 5 million
2009 23 million
2010 43 million
2011 52 million
2012 73 million
2013 108 million
2014 88 million
2015 81 million*
2016 43 million*

* ASAQ produced by Sanofi only. Statistics on generic ASAQ available from WHO after one year.

ASAQ is registered in:
Angola
Benin
Burundi
Burkina Faso
Cameroon
Central African Republic
Colombia
Congo
Côte d’Ivoire
DRC
Ecuador
Gabon
Ghana
Guinea
India
Kenya
Liberia
Madagascar
Malawi
Mali
Mauritania
Morocco
Mozambique
Niger
Nigeria
Senegal
Sierra Leone
South Sudan
Chad
Tanzania (+ Zanzibar)
Togo
Uganda
Zambia
Zimbabwe